Safety and Preliminary Activity of BI115 in Advanced SCLC

This study is a multi-regional, open-label phase I study to evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants with Advanced Small Cell Lung Cancer

Trial Details

NCT ID
NCT07559019
Phase
PHASE1
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • IBI115
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Participants must be able to understand and sign the written informed consent form for participation in this trial, including all evaluations and p…
  • Male or female participants aged ≥18 years and ≤75 years.
  • Participants with histologically or cytologically confirmed advanced small cell lung cancer.
  • At least one measurable lesion according to RECIST V1.1 within 28 days prior to the first dose of IBI115.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →